Novel diabetes hope comes from Chinese herbs

Aug 17, 2010

Emodin, a natural product that can be extracted from various Chinese herbs including Rheum palmatum and Polygonum cuspidatum, shows promise as an agent that could reduce the impact of type 2 diabetes. Findings published in this month's edition of the British Journal of Pharmacology show that giving emodin to mice with diet-induced obesity lowered blood glucose and serum insulin, improved insulin resistance and lead to more healthy levels of lipid in the blood. It also decreased body weight and reduced central fat mass.

"If repeated in humans, all of these changes would be beneficial for people affected by or other metabolic diseases associated with ," says lead author Dr Ying Leng, who works in the Shanghai Institute of Materia Medica, Chinese Academy of Science, Shanghai, China.

Research is increasingly showing that an enzyme known as 11β-HSD1 plays a role in the body's response to sugar contained in a person's diet. When someone eats sugar-containing food a lot of glucose floods into the blood stream. In response, the body releases insulin and this hormone triggers various actions that help to clear excess glucose from the blood. The body, however, also has another set of hormones known as glucocorticoids, which have the opposite effect to insulin. And this is where 11β-HSD1 fits in, because this enzyme increases glucocorticoids' ability to act.

The research revealed for the first time that emodin is a potent selective inhibitor of 11β-HSD1, and as a result it effectively limits the effect of the glucocorticoids, and ameliorates diabetes and resistance.

"Our work showed that this natural extract from Chinese herbs could point the way to a new way of helping people with type 2 as well as other metabolic disorders. To develop it further, researchers would need to develop chemicals that have similar effects as emodin, and see which if any of these could be used as a therapeutic drug," says Dr Leng.

Explore further: Rapivab approved to help treat flu

More information: Emodin, a natural product, selectively inhibits 11β-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice. Ying Feng, Su-ling Huang, Wei Dou, Song Zhang, Jun-hua Chen, Yu Shen, Jian-hua Shen, Ying Leng. British Journal of Pharmacology. 2010; 161: 113-126. DOI: DOI:10.1111/j.1476-5381.2010.00826.x

Related Stories

Apelin hormone injections powerfully lower blood sugar

Nov 04, 2008

By injecting a hormone produced by fat and other tissues into mice, researchers report in the November Cell Metabolism that they significantly lowered blood sugar levels in normal and obese mice. The findings suggest that t ...

Low doses of a red wine ingredient fight diabetes in mice

Oct 02, 2007

Even relatively low doses of resveratrol—a chemical found in the skins of red grapes and in red wine—can improve the sensitivity of mice to the hormone insulin, according to a report in the October issue of Cell Metabolism. As ins ...

Impaired fat-burning gene worsens diabetes

Feb 07, 2008

Researchers at the Swedish medical university Karolinska Institutet have in collaboration with researchers from Finland, China, Japan and the US discovered new cellular mechanisms that lead to in insulin resistance in people ...

How does insulin influence resistin?

Jan 16, 2008

Obesity is a worldwide health problem directly linked to several diseases such as hypertension and type 2 diabetes. Resistin is a cysteine-rich hormone mainly secreted by adipose tissues and may form a biochemical link between ...

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

13 hours ago

The nation's largest pharmacy benefits manager is throwing its weight into the fight over high-cost hepatitis C drugs with a coverage restriction that might ultimately lower prices and improve patient access ...

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.